ArticleAntimicrobial agents and chemotherapy1997
Molecular biological characterization of an azole-resistant Candida glabrata isolate.
Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed.
- Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistantmSphere · 2026Article
- Antifungal drug resistance in Candida glabrata: role of cellular signaling and gene regulatory networks.FEMS yeast research · 2025Review
- The rise and future of CRISPR-based approaches for high-throughput genomics.FEMS microbiology reviews · 2024Review
- Drivers of diversification in fungal pathogen populations.PLoS pathogens · 2024Review
- Multiple routes to fungicide resistance: Interaction of Cyp51 gene sequences, copy number and expression.Molecular plant pathology · 2024Article
- Article
- Long-term stability of acquired drug resistance and resistance associated mutations in the fungal pathogenFrontiers in cellular and infection microbiology · 2024Article
- Review
- Antifungal Drug Concentration Impacts the Spectrum of Adaptive Mutations in Candida albicans.Molecular biology and evolution · 2023Article
- Copy Number Variation and Allele Ratio Analysis in Candida albicans Using Whole Genome Sequencing Data.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Gene Amplification ofAntimicrobial agents and chemotherapy · 2022Article
- A New Variant of Mutational and Polymorphic Signatures in theInfection and drug resistance · 2022Article
- Prediction of Gene and Genomic Regulation in Candida Species, Using the PathoYeastract Database: A Comparative Genomics Approach.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Characterization of the Molecular Mechanisms of Resistance against DMI Fungicides inJournal of fungi (Basel, Switzerland) · 2021Article
- Two Sequential Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2021Article
- Antifungal Drug Resistance: Molecular Mechanisms inChemical reviews · 2021Review
- Identification of Essential Genes and Fluconazole Susceptibility Genes inG3 (Bethesda, Md.) · 2020Article
- Candida glabrata Transcription Factor Rpn4 Mediates Fluconazole Resistance through Regulation of Ergosterol Biosynthesis and Plasma Membrane Permeability.Antimicrobial agents and chemotherapy · 2020Article
- Review
- An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains.Journal of fungi (Basel, Switzerland) · 2020Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two isolates of Candida glabrata, one susceptible and one resistant to azole antifungals, were previously shown to differ in quantity and activity of the cytochrome P-450 14alpha-lanosterol demethylase which is the target for azole antifungals. The resistant isolate also had a lower intracellular level of fluconazole, but not of ketoconazole or itraconazole, than the susceptible isolate. In the present study a 3.7-fold increase in the copy number of the CYP51 gene, encoding the 14alpha-lanosterol demethylase, was found. The amount of CYP51 mRNA transcript in the resistant isolate was eight times greater than it was in the susceptible isolate. Hybridization experiments on chromosomal blots indicated that this increase in copy number was due to duplication of the entire chromosome containing the CYP51 gene. The phenotypic instability of the resistant isolate was demonstrated genotypically: a gradual loss of the duplicated chromosome was seen in successive subcultures of the isolate in fluconazole-free medium and correlated with reversion to susceptibility. The greater abundance of the amplified chromosome induced pronounced differences in the protein patterns of the susceptible and revertant isolates versus that of the resistant isolate, as demonstrated by two-dimensional gel electrophoresis (2D-GE). Densitometry of the 2D-GE product indicated upregulation of at least 25 proteins and downregulation of at least 76 proteins in the resistant isolate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.